Suvorexant, a dual orexin receptor antagonist, protected seizure through interaction with GABAA and glutamate receptors

Document Type : Research article

Authors

1 Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Mdical sciences,Mashhad,Iran.

2 Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad

3 Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Mdical sciences,Mashhad,Iran.Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Orexin can increase neuronal excitability and induce epileptic activity. In this study, the effects of suvorexant (orexin receptor antagonist) on pentylenetetrazol (PTZ) and maximal electroshock (MES)-induced seizure were investigated. Mice were divided into 5 groups of six animals each including normal saline (10 ml/kg), diazepam (2 mg/kg) and suvorexant (50, 100 and 200 mg/kg) groups. In PTZ test, the latency to first minimal clonic seizure (MCS), latency to the first generalized tonic–clonic seizures (GTCS), total duration of seizure and also protection against mortality were evaluated. In MES, the hind limb tonic extension (HLTE) and the protection against mortality were recorded. In order to evaluate the role of GABAA in anticonvulsant effect of suvorexant, flumazenil was used and to investigate the role of glutamate, the protein levels of AMPAR and NMDAR were measured in hippocampus by western blotting. In PTZ model, suvorexant (200mg/kg) increased MCS and GTCS latencies. Suvorexant (100 and 200 mg/kg) decreased total duration of seizure compared to control group. In PTZ model, flumazenil inhibited the prolongation of seizure latency induced by suvorexant. In MES, the HLTE was decreased by suvorexant (100 and 200 mg/kg) and suvorexant protected against mortality by 83.3%. Moreover, the protein levels of NMDAR and AMPAR were decreased by suvorexant.
Suvorexant exerted anticonvulsant activity and in addition to its inhibitory effect on orexin receptors, this effect may be mediated, at least partly, through interaction with GABAA and glutamate receptors.

Graphical Abstract

Suvorexant, a dual orexin receptor antagonist, protected seizure through interaction with GABAA and glutamate receptors

Keywords


(1)        Avanzini G and Franceschetti S. Cellular biology of epileptogenesis. Lancet. Neurol.(2003) 2:33-42.
(2)        Banerjee PN, Filippi D and Allen Hauser W. The descriptive epidemiology of epilepsy-a review. Epilepsy res.(2009) 85:31-45.
(3)        Laxer KD, Trinka E, and Hirsch L. The consequences of refractory epilepsy and its treatment. Epilepsy Behav.(2014) 37:59–70.
(4)        Sakurai T, Amemiya A and Ishii M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G proteincoupled receptors that regulate feeding behavior. Cell (1998) 92:573-85.
(5)        Chiou LC, Lee HJ, Ho YC, Chen SP, Liao YY, Ma CH, et al. Orexins/hypocretins: pain regulation and cellular actions. Curr. Pharm. Des. (2010) 16:3089-100.
(6)        Razavi BM and Hosseinzadeh H. A review of the role of orexin system in pain modulation. Biomed. Pharmacother. (2017) 90:187-93.
(7)        Ni L, Zhu M, Song Y, Liu Z and Tang J. Pentylenetetrazol-induced seizures are exacerbated by sleep deprivation through orexin receptor-mediated hippocampal cell proliferation. Neurol. Sci. (2014) 35:245–52.
(8)        Ida T, Nakahara K, Katayama T, Murakami N and Nakazato M. Effect of lateral cerebroventricular injection of the appetitestimulating neuropeptide, orexin and neuropeptide Y, on the various behavioral activities of rats. Brain Res.(1999) 821:526–9.
(9)        Erken HA, Erken G, and Genc O. Orexins cause epileptic activity. Peptides.(2012) 37:161–4.
(10)      Kortunay S, Erken H, Erken G, Genç O, Şahiner M, Turgut S, et al. Orexins increase penicillin-induced epileptic activity. Peptides.(2012) 34:419-22.
(11)      Goudarzi E, Elahdadi Salmani M, Lashkarbolouki Tand Goudarzi I. Hippocampal orexin receptors inactivation reduces PTZ induced seizures of male rats. Pharmacol.Biochem. Behav.(2015) 130:77-83.
(12)   Hayatdavoudi P, Sadeghnia HR, Mohamadian-Roshan N and Hadjzadeh MA. Beneficial Effects of Selective Orexin-A Receptor Antagonist in 4-aminopyridine-induced Seizures in Male Rats. Adv. Biomed. Res. (2017) 6:162. 
(13)      Christopher JA. Small-molecule antagonists of the orexin receptors. Pharm. Pat.anal.(2014) 3:625-38.
(14)      Zolfagharian F, Razavi BM and Hosseinzadeh H. Anticonvulsant effect of Satureja hortensis aerial parts extracts in mice. Avicenna j. phytomed.(2016) 6:305-12.
(15)      Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, et al. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J. Neurogen.(2011) 25:52-61.
(16)      Hosseinzadeh Hand Sadeghnia H. Protective effect of safranal on pentylenetetrazol-induced seizures in the rat: Involvement of GABAergic and opioids systems. Phytomedicine. (2007) 14:256-62.
(17)      Boss Cand Roch C. Recent trends in orexin research—2010 to 2015. Bioorg. Med. Chem. Lett.(2015) 25:2875-87.
(18)      Rejdak K, Papuc E, Grieb P and Stelmasiak Z. Decreased cerebrospinal fluid hypocretin-1 (orexin A) in patients after repetitive generalized tonic–clonic seizures. Epilepsia.(2009) 50:1641–4.
(19)      Kordi Jaz E, Moghimi A, Fereidoni M, Asadi S, Shamsizadeh A and Roohbakhsh A. SB-334867, an orexin receptor 1 antagonist, decreased seizure and anxiety in pentylenetetrazol-kindled rats. Fund.clin. pharmacol.(2017) 31:201-7.
(20)     Asadi S, Roohbakhsh A, Shamsizadeh A, Fereidoni M, Kordijaz E and Moghimi A. The effect of intracerebroventricular administration of orexin receptor type 2 antagonist on pentylenetetrazol-induced kindled seizures and anxiety in rats. BMC neurosci. (2018) 19:49.
(21)      Selbach O, Doreulee N, Bohla C, Eriksson KS, Sergeeva OA, Poelchen W, et al. Orexins/hypocretins cause sharp wave- and theta-related synaptic plasticity in the hippocampus via glutamatergic, gabaergic, noradrenergic, and cholinergic signaling. Neuroscience.(2004) 127:519-28.
(22)      Akbari N, Salmani M, Goudarzvand M, LashkarBoluki T, Goudarzi I and Akbari K. Unilateral hypothalamus inactivation prevents PTZ kindling development through hippocampal orexin receptor 1 modulation. Basic Clin. Neurosci. (2014) 5:66–73.
(23)      Kodama T and Kimura M. Arousal effects of orexin-A correlate with GLU release from the locus coeruleus in rats. Peptides.(2002) 23:1673–81.